Virtual Library
Start Your Search
Andriani Charpidou
Author of
-
+
EP1.01 - Advanced NSCLC (ID 150)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.01-69 - Safety and Efficacy of Percutaneous Computed Tomography-Guided Thermal Ablation of Non-Small Cell Lung Cancer Metastases (Now Available) (ID 1147)
08:00 - 18:00 | Author(s): Andriani Charpidou
- Abstract
Background
Percutaneous computed tomography-guided (CT-guided) thermal ablation is a minimally invasive method for the treatment of adrenal metastases, painful bone metastases and liver metastases originating from non-small cell lung cancer (NSCLC). We aimed to further evaluate the safety and efficacy of CT-guided radiofrequency ablation (RFA) and microwave ablation (MWA) in the management of metastases in a real-life cohort of NSCLC patients.
Method
The medical records of 142 patients with metastatic NSCLC (71, 32 and 40 patients with adrenal metastases, painful bone metastases and liver metastases, respectively) treated with CT-guided RFA or MWA were retrospectively studied. The efficacy of thermal ablation was evaluated by post-ablation imaging. For painful bone metastases, palliation was assessed by the Brief Pain Inventory (BPI) score.
Result
Technical success of CT-guided thermal ablation was 100%. No major complications occurred. Among patients with adrenal metastases treated with RFA or MWA, local recurrence was observed in 17.1% and 19.4% of cases at 1-year follow up, respectively. In patients with painful bone metastases, significant pain relief was noted after thermal ablation (p<0,001). Local recurrence was observed in 3.3% of cases with liver metastases at 1-year follow-up.
Conclusion
CT-guided RF and MW ablation is a safe and effective local treatment for the management of adrenal, bone and liver metastases from NSCLC. For painful bone metastases RF ablation provides significant pain relief.
-
+
P2.01 - Advanced NSCLC (ID 159)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.01-54 - Real-World PD-L1 Testing Patterns for Patients with Advanced Non-Small Cell Lung Cancer in Greece (ID 2138)
10:15 - 18:15 | Author(s): Andriani Charpidou
- Abstract
Background
Programmed Cell Death Protein-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) inhibitors are important immunotherapy targets for non-small cell lung cancer (NSCLC). This study sought to describe PD-L1 testing for patients with NSCLC in Greece.
Method
This non-interventional study is based on Sotiria Lung Cancer Registry in Greece recording patients with histologically or cytologically confirmed stage IIIB/IV NSCLC diagnosis, who initiated systemic treatment between August, 15th 2016 and August, 14th 2018.
Result
A total of 472 patients were included in the registry. Demographic and first-line treatment information are presented in Table 1, along with the respective comparison between patients tested and not tested for PD-L1. Patients with ECOG PS 0-1 are more likely to be tested for PD-L1 status. Among patients tested for PD-L1, Dako 22C3 was the most commonly used testing assay (87.8%).
The number of patients tested for PD-L1 increased between the two consecutive time periods (from August, 15th 2016 to August, 14th 2018; Table 2).
Conclusion
The percentage of newly diagnosed patients with advanced NSCLC in Greece tested for PD-L1 status doubled in a year (August, 15th 2016 – August, 14th 2018). Among those tested, 67% were tested prior to first-line treatment initiation and 26% of those tested had PD-L1 TPS ≥50%.
